NASDAQ:BCLI
READ THE FULL BCLI RESEARCH REPORT
Business Update
Phase 3b Trial Design Announced; SPA Submitted to the FDA
On March 4, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) presented a poster at the MDA Clinical and Scientific Conference with an outline of the proposed design for a Phase 3b trial of NurOwn® (debamestrocel) in amyotrophic lateral sclerosis (ALS).
The following figure gives an overview of the proposed trial design, which is now under review by the U.S. Food and Drug Administration (FDA). Up to approximately 200 patients with mild-to-moderate ALS will be enrolled into the two-part study: Part A will be a 24-week, randomized, double blind period while Part B will be a 24-week open-label extension period. The primary endpoint will be based on the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). Patients will be treated at Weeks 0, 8, and 16 during Part A and then Weeks 24, 32, and 40 in Part B.
In February 2024, BrainStorm announced it submitted a Special Protocol Assessment (SPA) to the U.S. FDA regarding the design of the Phase 3b trial. Participating in the SPA program will allow BrainStorm to reach a consensus with the FDA on the Phase 3b trial design and ensure that the study is considered adequate by the FDA to support a future marketing evaluation. A response from the FDA is anticipated within 45 days of submission and the company will then take any feedback into consideration before finalizing the design of the trial.
As a reminder, when examining patients with a baseline ALSFRS-R ≥ 35 in the Phase 3 trial, patients treated with NurOwn exhibited a clinical response 2x higher than placebo and had a significantly slower rate of ALS progression, as shown in the following figure. This supports the company’s decision to include patients with mild-to-moderate ALS in the Phase 3b trial.
Conclusion
We look forward to an update regarding the FDA’s feedback on the SPA and the finalized design for the Phase 3b trial along with guidance on when the trial is expected to initiate. Participating in the SPA program is a smart strategic move as agreement with the FDA on the design for a Phase 3 program will help to de-risk certain regulatory aspects of the program. With the SPA being submitted and a response expected soon from the FDA, we have increased our valuation to $1.00 per share.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
